Peptide-loaded Major Histocompatibility Complex class I (pMHC-I) on autologous dendritic cells (pMHC-I on autologous DCs)

Peptide-loaded Major Histocompatibility Complex (MHC) class I on autologous dendritic cells is a therapeutic configuration used in personalized cancer immunotherapy (Banchereau & Steinman, 1998). This approach involves isolating a patient's own dendritic cells, which are the most potent antigen-presenting cells of the immune system, and maturing them ex vivo (Palucka & Banchereau, 2012). These cells are then loaded or "pulsed" with specific synthetic peptides representing tumor-associated antigens (TAAs) or viral proteins. Once re-infused into the patient, these dendritic cells present the peptide-MHC class I complexes directly to CD8+ T cells, triggering the expansion of antigen-specific cytotoxic T lymphocytes (CTLs) capable of recognizing and lysing target cells (Rock et al., 2016). The biological function of this complex is to initiate a targeted adaptive immune response by providing the necessary TCR binding signal and co-stimulatory support. It is primarily utilized in clinical trials for solid tumors such as melanoma, glioblastoma, and prostate cancer to overcome immune tolerance (Kantoff et al., 2010). While promising, the efficacy of this modality is often challenged by the immunosuppressive nature of the tumor microenvironment and the complexity of autologous cell manufacturing.

Other names

Dendritic cell vaccinePeptide-pulsed dendritic cellsAutologous DC-based immunotherapyAntigen-presenting cell vaccineDC-based cancer vaccine

Induction of antigen-specific cytotoxic T lymphocyte (CTL) responses through the presentation of peptide-MHC class I complexes to CD8+ T cells.